| Miss Emily Carol Chandler, MCD CCC-SLP | |
|
1007 Goodyear Ave, Gadsden, AL 35903-1195 | |
| (256) 494-4160 | |
| (256) 442-8106 |
| Full Name | Miss Emily Carol Chandler |
|---|---|
| Gender | Female |
| Speciality | Speech-language Pathologist |
| Location | 1007 Goodyear Ave, Gadsden, Alabama |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1346542644 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 235Z00000X | Speech-language Pathologist | 2810 (Alabama) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Miss Emily Carol Chandler, MCD CCC-SLP 3102 Rainbow Dr, Rainbow City, AL 35906-5804 Ph: (256) 413-7422 | Miss Emily Carol Chandler, MCD CCC-SLP 1007 Goodyear Ave, Gadsden, AL 35903-1195 Ph: (256) 494-4160 |
News Archive
Millions of U.S. drivers cross faulty or obsolete bridges every day, highway statistics show, but it's too costly to fix all these spans or adequately monitor their safety, says a University of Maryland researcher who's developed a new, affordable early warning system.
Researchers from North Carolina State University and Mayo Clinic have developed a computer model that medical doctors can use to determine the best time to begin using statin therapy in diabetes patients to help prevent heart disease and stroke.
Abaloparatide-SC, an injectable drug being studied for the treatment of postmenopausal osteoporosis, reduces the rate of new spinal fractures by a statistically significant 86 percent and as well as statistically significant reductions in the fracture rate at other parts of the body, a phase 3 clinical trial finds. Results of the ACTIVE fracture prevention trial will be described in a late-breaking oral presentation Thursday at the Endocrine Society's 97th annual meeting in San Diego.
European research lays the foundation for the development of new and ambitious research projects with xenografts derived from patients, preclinical models with great potential to advance research and treatment in cancer.
BioCryst Pharmaceuticals, Inc. today announced that its partner, Shionogi & Co., Ltd. has filed a New Drug Application (NDA) in Japan to seek regulatory approval for intravenous (i.v.) peramivir to treat patients with influenza. As a consequence of this filing, BioCryst will receive a regulatory milestone payment of $7 million under its agreement with Shionogi.
› Verified 8 days ago
Melissa Gordon Reynolds, MS CCC/SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 3224 Rainbow Dr, Gadsden, AL 35906 Phone: 256-553-9882 | |
Ms. Ashley Cole, M.S., CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1181 Wilson St, Gadsden, AL 35901 Phone: 256-557-5541 | |
Kendall Purcell, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 2301 Rainbow Dr, Gadsden, AL 35901 Phone: 256-543-3467 | |
Lacey Seawright Gulling, SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1007 Goodyear Ave, Gadsden, AL 35903 Phone: 256-413-6060 Fax: 256-413-6066 | |
Megan Elliott, M.S., CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1007 Goodyear Ave, Gadsden, AL 35903 Phone: 256-413-6060 | |
Diversicare Rehabilitation Services Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 700 Hutchins Ave, Gadsden, AL 35901 Phone: 256-543-7101 |